anti-CD22/anti-CD28 bispecific antibody REGN5837

{
  "id": "MLC-T-ONC-010314",
  "term": "anti-CD22/anti-CD28 bispecific antibody REGN5837",
  "field": "Oncology and biomedicine",
  "definition": "A hinge-stabilized human immunoglobulin G4 (IgG4) bispecific antibody directed against both the tumor-associated antigen (TAA) CD22 and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD22/anti-CD28 bispecific antibody REGN5837 targets and binds to both CD28 expressed on T cells and CD22 expressed on tumor cells, which crosslinks the T cells to the tumor cells. This may result in the activation of a cytotoxic T-lymphocyte (CTL) response against the CD22-expressing tumor cells. CD22 is exclusively expressed on B cells and is often overexpressed in B-lymphocytic malignancies. It negatively regulates the B-cell receptor.",
  "synonyms": [
    "anti-CD22 x anti-CD28 costimulatory bispecific monoclonal antibody REGN5837",
    "anti-CD22/CD28 bispecific antibody REGN5837"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-cd22-anti-cd28-bispecific-antibody-regn5837/"
}